Breast Cancer Causes and Risk Factors: What Increases Your Risk

Key Takeaways

• Breast cancer does not have a single cause — it develops from an accumulation of genetic mutations influenced by age, hormonal exposure, family history, lifestyle, and environmental factors.

• Most breast cancers (85–90%) are not inherited. About 5–10% are linked to inherited gene mutations such as BRCA1 or BRCA2.

• Age is the single greatest risk factor: the majority of breast cancer diagnoses occur in women over 50.

• Several risk factors are modifiable like, limiting alcohol, maintaining a healthy weight after menopause, staying physically active, and breastfeeding have all been shown to reduce risk.

• Dense breast tissue raises both breast cancer risk and the difficulty of detecting it on standard mammography. If you have dense breasts, ask your doctor about supplemental screening.

• Having risk factors does not mean you will develop breast cancer; having few risk factors does not mean you won’t. Risk reflects probability, not certainty.

What Causes Breast Cancer?

Breast cancer begins when cells in the breast acquire genetic mutations that cause them to grow and divide uncontrollably. These mutations can arise in two ways: they may be inherited — present from birth and passed down through families — or they may be acquired during a person’s lifetime through a combination of hormonal exposures, aging, lifestyle factors, and random cellular errors that accumulate over time.

The vast majority of breast cancers, roughly 85 to 90%, according to the National Cancer Institute, are not inherited. They develop sporadically, meaning the mutations driving them were not present at birth. The remaining 10 to 15% occur in people with an inherited gene mutation that significantly raises lifetime risk.

Understanding breast cancer risk factors is not about predicting the future. It is about knowing which factors increase probability, which can be modified, and how to make informed decisions about screening, prevention, and when to consider genetic testing.

Genetic and Hereditary Risk Factors

BRCA1 and BRCA2 Mutations

The most well-known hereditary risk factors for breast cancer are mutations in the BRCA1 and BRCA2 genes. These genes normally produce proteins that help repair damaged DNA, acting as tumor suppressors. When a mutation impairs this function, the risk of cancer increases substantially.

According to the National Cancer Institute, women with a BRCA1 mutation have a 55–72% lifetime risk of developing breast cancer; those with a BRCA2 mutation have a 45–69% lifetime risk — compared with approximately 12% for the average-risk population. BRCA mutations also significantly raise ovarian cancer risk.

BRCA1 mutations are particularly associated with triple-negative breast cancer, while BRCA2 mutations more commonly connect to hormone receptor-positive disease. Together, BRCA1 and BRCA2 account for roughly 5–10% of all breast cancer diagnoses.

Other Hereditary Gene Mutations

BRCA1 and BRCA2 are not the only genes that matter. Several additional mutations are associated with meaningfully elevated breast cancer risk:

• PALB2: Works in concert with BRCA2 in DNA repair. Mutations are associated with a lifetime breast cancer risk of approximately 35–58%, according to published data from the PALB2 Interest Group.

• CHEK2: A moderately penetrant gene; mutations roughly double lifetime breast cancer risk, primarily for hormone receptor-positive disease.

• ATM: Heterozygous mutations are associated with moderately elevated risk, particularly for hormone receptor-positive breast cancer.

• TP53: Rare Li-Fraumeni syndrome mutations carry a lifetime breast cancer risk as high as 85%, along with elevated risks for other cancers.

• PTEN: Cowden syndrome, caused by PTEN mutations, carries a 25–50% lifetime risk of breast cancer.

Comprehensive multi-gene panel testing is now widely available and recommended by NCCN guidelines for individuals who meet criteria based on personal or family history. A genetic counselor can help determine whether testing is right for you.

Family History

A family history of breast cancer raises risk even without an identified gene mutation. According to the American Cancer Society, having one first-degree relative (mother, sister, or daughter) with breast cancer approximately doubles a woman’s risk. Having two first-degree relatives with breast cancer raises it further.

Paternal family history matters as well. BRCA mutations can be inherited from either parent. Family history of ovarian cancer, male breast cancer, or breast cancer diagnosed before age 50 are particularly important signals that may point to an inherited syndrome worth evaluating.

Hormonal Risk Factors

The relationship between estrogen, progesterone, and breast cancer risk is well-established. Many of the most significant risk factors relate to cumulative hormonal exposure over a lifetime.

Reproductive History

Earlier age at first menstrual period (before age 12) and later age at menopause (after age 55) both extend the window of lifetime estrogen and progesterone exposure, modestly increasing breast cancer risk. Timing and pregnancy history also play a role:

• Having children: Women who have had children have a somewhat lower lifetime risk than women who have not, likely due to the hormonal changes of pregnancy and their effect on breast cell maturation.

• Age at first full-term pregnancy: Women who have their first full-term pregnancy before age 30 appear to have a lower long-term risk than those who give birth after 30 or do not carry a pregnancy to term.

• Breastfeeding: Breastfeeding reduces breast cancer risk in a dose-dependent way — the longer a woman breastfeeds over her lifetime, the greater the apparent risk reduction, likely due to delayed return of menstrual cycles during lactation and differentiation of breast cells during milk production.

Hormone Therapy

The relationship between menopausal hormone therapy and breast cancer risk depends on the type and duration of use:

• Combined estrogen-progestin therapy: Associated with a small but real increase in breast cancer risk with long-term use (more than five years). The landmark Women’s Health Initiative randomized trial identified a modestly elevated risk in women using combined hormone therapy.

• Estrogen-only therapy: Used primarily in women who have had a hysterectomy. Long-term use has been associated with a small increase in risk in some studies, though lower than with combined therapy.

• Oral contraceptives: Current or recent use is associated with a slight increase in breast cancer risk. Risk returns to baseline within approximately 10 years of stopping.

This does not mean hormone therapy is wrong for every woman — the decision involves weighing individual benefits (relief of menopausal symptoms, bone protection) against risks, in the context of personal and family history. This is a conversation best had with your physician.

Lifestyle and Environmental Risk Factors

Alcohol

Alcohol is one of the most clearly established modifiable risk factors for breast cancer. According to the American Cancer Society, each alcoholic drink per day is associated with approximately a 7–10% increase in breast cancer risk — a dose-dependent relationship with no established safe threshold. Women who have two to three drinks per day have roughly a 20% higher risk than non-drinkers. The likely mechanisms include elevated circulating estrogen levels, generation of reactive oxygen species that can damage DNA, and impaired folate metabolism.

Weight and Physical Activity

Excess body weight after menopause is an established breast cancer risk factor. Adipose (fat) tissue is a significant source of estrogen after menopause — greater adipose tissue means higher estrogen levels and elevated risk of hormone receptor-positive breast cancer. According to the American Cancer Society, postmenopausal women who are overweight or obese have a 20–40% higher risk of breast cancer compared with postmenopausal women at a healthy weight.

Physical activity consistently shows a protective association across epidemiological studies. Women who engage in regular physical activity have approximately a 10–20% lower risk of breast cancer than sedentary women, with greater effects at higher activity levels.

Radiation Exposure

Exposure to ionizing radiation — particularly to the chest — increases breast cancer risk, especially when exposure occurs during adolescence and young adulthood when breast tissue is most sensitive. Women who received radiation therapy to the chest for conditions such as Hodgkin lymphoma before age 30 have a significantly elevated lifetime breast cancer risk and should follow enhanced surveillance guidelines. Diagnostic imaging such as standard mammograms involves much lower radiation doses and is not associated with meaningful risk elevation.

Non-Modifiable Risk Factors

Age

Age is the single greatest risk factor for breast cancer. Fewer than 5% of breast cancers occur in women under 40. Risk rises sharply with age: according to the American Cancer Society, the probability of developing invasive breast cancer is approximately 1 in 227 for women in their 30s, rising to 1 in 29 for women in their 60s. This is why regular screening mammography beginning at age 40, per American Cancer Society guidelines, is so important.

Dense Breast Tissue

Dense breast tissue, which is characterized by more glandular and fibrous tissue relative to fatty tissue, is both a risk factor for breast cancer and a barrier to early detection on standard mammography. Women with very dense breasts have a breast cancer risk approximately 1.5–2 times higher than women with average density. Dense tissue also makes tumors harder to see on a mammogram, because both appear white. Several states require that women be informed of their breast density on mammogram reports. If you have dense breasts, ask your doctor whether supplemental screening with ultrasound or MRI is appropriate for you.

Personal and Medical History

A prior breast cancer diagnosis increases the risk of developing a new breast cancer in the same or opposite breast. Certain benign breast conditions also affect risk: atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) are each associated with approximately a 3.5–5 times higher risk of subsequent breast cancer compared with the general population. Prior chest radiation, as described above, is also a significant independent risk factor.

Race and Ethnicity

White women have the highest overall incidence of breast cancer in the United States, but Black women have a higher overall mortality rate and are significantly more likely to be diagnosed with triple-negative breast cancer — a more aggressive subtype. Disparities in access to screening, timely diagnosis, and high-quality treatment contribute meaningfully to this mortality gap. Ashkenazi Jewish women have a higher prevalence of specific BRCA1 and BRCA2 founder mutations and should discuss genetic testing with their physician.

Understanding Your Personal Risk

No single risk factor predicts breast cancer with certainty. Risk is best understood as a combination of factors, and several validated tools exist to estimate individual probability:

• Tyrer-Cuzick model (IBIS risk calculator): Incorporates family history, personal history, hormonal factors, and breast density to estimate 10-year and lifetime risk.

• Gail model (NCI Breast Cancer Risk Assessment Tool): Estimates 5-year and lifetime risk based on age, reproductive history, family history, and biopsy history.

• BOADICEA model: Designed for families with a significant history across multiple relatives; incorporates genes beyond BRCA1/2.

Women at high lifetime risk (≥20% by validated models, or with a known BRCA mutation or equivalent) are eligible for annual breast MRI in addition to mammography, per American Cancer Society guidelines.

If you have a significant personal or family history, ask for a referral to a genetic counselor. Multi-gene panel testing can identify mutations in BRCA1, BRCA2, PALB2, CHEK2, ATM, and other genes. This information can shape both your own decisions and those of family members.

Understanding your risk profile also shapes your eligibility for clinical trials, including prevention trials, high-risk surveillance trials, and early-detection studies. Exploring breast cancer clinical trials is a meaningful step for anyone at elevated risk. Ready to see which trials may be relevant for you? Start your search with North’s trial finder.

Frequently Asked Questions

What is the number one cause of breast cancer?

There is no single cause. Breast cancer develops from an accumulation of genetic mutations influenced by age, hormonal exposure, family history, and lifestyle factors. Age is the largest single risk factor — the majority of diagnoses occur in women over 50. Inherited gene mutations such as BRCA1 or BRCA2 account for about 5–10% of cases, with most breast cancers developing sporadically rather than through hereditary pathways.

Does having a family history of breast cancer mean I will get it?

Not necessarily. A family history raises your statistical risk but does not determine your outcome. Having one first-degree relative with breast cancer approximately doubles your lifetime risk compared with the general population — raising it from roughly 12% to approximately 24%. Genetic counseling can help clarify your individual risk and whether testing for inherited mutations is appropriate for your situation.

Can lifestyle changes prevent breast cancer?

Lifestyle changes can meaningfully reduce risk but cannot guarantee prevention. Limiting alcohol, maintaining a healthy weight after menopause, staying physically active, and breastfeeding have all been associated with reduced breast cancer risk in large epidemiological studies. Even so, breast cancer occurs in women with no known risk factors — which is why regular screening remains important for everyone, regardless of lifestyle.

What does breast density have to do with breast cancer risk?

Dense breast tissue is associated with a modestly higher risk of developing breast cancer, and it also makes it harder for standard mammography to detect tumors — both dense tissue and tumors appear white on a mammogram. If your mammogram report indicates you have dense breasts, talk to your doctor about whether supplemental screening with ultrasound or MRI is right for you.

Should I get genetic testing for BRCA mutations?

BRCA testing — and broader multi-gene panel testing — is recommended for individuals with certain personal or family history features: breast cancer diagnosed before age 50, ovarian cancer at any age, male breast cancer, multiple relatives with breast or ovarian cancer, Ashkenazi Jewish heritage with a family history of either cancer, or a known BRCA mutation in the family. Testing is typically initiated through genetic counseling. Your oncologist or primary care physician can help determine whether you meet criteria.

References

1. American Cancer Society. (2024). Breast Cancer Risk Factors You Cannot Change. https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html

2. American Cancer Society. (2024). Lifestyle-Related Breast Cancer Risk Factors. https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/lifestyle-related-breast-cancer-risk-factors.html

3. National Cancer Institute. (2024). BRCA Gene Mutations: Cancer Risk and Genetic Testing. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet

4. Antoniou, A., et al. (2003). Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History. American Journal of Human Genetics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1180281/

5. Renwick, A., et al. (2006). ATM Mutations That Cause Ataxia-Telangiectasia Are Breast Cancer Susceptibility Alleles. Nature Genetics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667301/

6. Gradishar, W. J., et al. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419

7. Rossouw, J. E., et al. (2002). Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/195120